Business Context and Reporting Period
This Form 6-K filing by Xiaobai Maimai Inc. (referred to in metadata as Akso Health Group) covers the month of August 2021, with the report signed on August 12, 2021. The filing discloses the entry into a material definitive agreement regarding a private placement of securities.
Key Financial Metrics
The filing details a capital raise rather than operational financial performance. Key metrics include:
- Aggregate Purchase Price: Approximately $10.02 million.
- Net Proceeds: Approximately $10.00 million.
- Units Sold: 6,340,000 units.
- Price Per Unit: $1.58.
- Unit Composition: One ordinary share and one warrant to purchase three shares.
- Warrant Exercise Price: $3.00 per share.
The filing text does not provide clear values for revenue, profit, cash flow, margins, existing debt, or liquidity ratios.
Material Changes
The primary material change is the execution of a Securities Purchase Agreement (SPA) on August 9, 2021, with certain "non-U.S. Persons." This transaction increases the company's capital base and alters its capital structure through the issuance of new shares and warrants. The filing does not provide comparative data against a prior period for operational metrics.
Guidance, Outlook, and Risks
Use of Proceeds: Net proceeds will be used for working capital and general corporate purposes.
Warrant Terms: Warrants are exercisable immediately for cash. Cashless exercise is permitted after six months if no effective registration statement is available. Warrants expire five years from issuance and include anti-dilution provisions.
Conditions to Closing: The transaction is subject to Nasdaq's approval of the supplemental listing application for the Units and the accuracy of representations and warranties.
Risks and Contingencies: The filing notes customary representations regarding the absence of undisclosed material adverse effects and legal proceedings affecting the transaction. The filing text does not provide specific forward-looking guidance on future revenue or earnings.
Investor Verification Checklist
- Verify the final closing of the transaction and receipt of the $10.00 million net proceeds.
- Confirm Nasdaq's approval of the supplemental listing application for the Units.
- Review the full text of the Securities Purchase Agreement (Exhibit 99.1) and Warrant (Exhibit 99.2) for specific covenants and redemption rights.
- Monitor the company's capital structure for dilution resulting from the 6,340,000 new shares and potential warrant exercises.